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Introduction
Tree nuts are considered to be one of the most allergenic 
plant foods [1] and are an important cause of anaphylaxis [2]. 
Peanuts are a member of the Leguminosae family, and grow 
underground, unlike other nuts such as walnuts. They are, 
however, widely consumed and frequently found together with 
other tree nuts such as hazelnuts and walnuts. For practical 
purposes, peanuts will be considered tree nuts for the purpose 
of this study.
The use of component-resolved diagnosis (CRD) has 
improved the diagnosis of food allergies, as different allergenic 
profiles have been reported to be related to particular types of 
clinical reactivity [3-5]. Furthermore, differences in allergenic 
profiles have been described for different geographical 
regions [6,7]. Lipid transfer proteins (LTPs) are the main 
allergens in tree nut allergy in the Mediterranean area [6,8,9], 
although it has been suggested that LTPs might also be markers 
of peach sensitization in the absence of clinical allergy [8,10]. 
In this scenario, multiplex platforms for the quantitative 
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Background: Component-based diagnosis on multiplex platforms is widely used in food allergy but its clinical performance has not been 
evaluated in nut allergy.
Objective: To assess the diagnostic performance of a commercial protein microarray in the determination of specific IgE (sIgE) in peanut, 
hazelnut, and walnut allergy. 
Methods: sIgE was measured in 36 peanut-allergic, 36 hazelnut-allergic, and 44 walnut-allergic patients by ISAC 112, and subsequently, 
sIgE against available components was determined by ImmunoCAP in patients with negative ISAC results. ImmunoCAP was also used to 
measure sIgE to Ara h 9, Cor a 8, and Jug r 3 in a subgroup of lipid transfer protein (LTP)-sensitized nut-allergic patients (positive skin prick 
test to LTP-enriched extract). sIgE levels by ImmunoCAP were compared with ISAC ranges. 
Results: Most peanut-, hazelnut-, and walnut-allergic patients were sensitized to the corresponding nut LTP (Ara h 9, 66.7%; Cor a 8, 
80.5%; Jug r 3, 84% respectively). However, ISAC did not detect sIgE in 33.3% of peanut-allergic patients, 13.9% of hazelnut-allergic 
patients, or 13.6% of walnut-allergic patients. sIgE determination by ImmunoCAP detected sensitization to Ara h 9, Cor a 8, and Jug r 3 in, 
respectively, 61.5% of peanut-allergic patients, 60% of hazelnut-allergic patients, and 88.3% of walnut-allergic patients with negative 
ISAC results. In the subgroup of peach LTP–sensitized patients, Ara h 9 sIgE was detected in more cases by ImmunoCAP than by ISAC 
(94.4% vs 72.2%, P<.05). Similar rates of Cor a 8 and Jug r 3 sensitization were detected by both techniques.
Conclusions: The diagnostic performance of ISAC was adequate for hazelnut and walnut allergy but not for peanut allergy. sIgE sensitivity 
against Ara h 9 in ISAC needs to be improved.
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Introducción: La utilidad clínica del diagnóstico por componentes no ha sido evaluada en el estudio de la alergia a frutos secos (FS). 
Objetivo: Evaluar la capacidad diagnóstica de una micromatriz comercial de proteínas alergénicas en la alergia a cacahuete, avellana y nuez. 
Métodos: Se determinó la sIgE en pacientes alérgicos a FS mediante la micromatriz ISAC 112, e ImmunoCAP en los pacientes con sIgE 
negativa frente a los componentes de ISAC. Además, se realizó ImmunoCAP frente a Ara h 9, Cor a 8 y Jug r 3 en un subgrupo de pacientes 
sensibilizados a LTP. La sIgE detectada por ImmunoCAP fue comparada con los rangos de ISAC. 
Resultados: La mayoría de los alérgicos a cacahuete (66,7%), avellana (80,5%) y nuez (84%) estaba sensibilizados a su LTP. Sin embargo, 
no se detectó sIgE frente a los componentes de ISAC en el 33,3% de alérgicos a cacahuete, 13,9% de alérgicos a avellana y 13,6% de 
los alérgicos a nuez. El ImmunoCAP permitió detectar sIgE a Ara h 9 en 61,5%, Cor a 8 en 60% y Jug r 3 en 83,3% de los ISAC negativo. 
En el subgrupo LTP, ImmunoCAP (94,4%) fue superior a ISAC (72,2%) en la detección de sIgE a Ara h 9 (p<0,05). La sIgE frente a Cor a 8 
y Jug r 3 fue detectada de forma similar por ambas técnicas. 
Conclusiones: La micromatriz ISAC es adecuada para el diagnóstico de alergia a avellana y nuez. La sensibilidad del componente Ara h 9 
de ISAC debe ser mejorada.
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determination of specific IgE (sIgE) are useful, since sIgE 
against LTPs and other nut components can be measured in 
a single test.
It is accepted that CRD, through protein microarrays, offers 
the possibility of analyzing sIgE against multiple allergens, 
bringing the allergist closer to more individualized diagnoses 
and thus allowing a more tailored approach to allergy treatment 
and management [11]. However, despite the widespread use of 
CRD in clinical practice, few studies have analyzed the clinical 
utility of the commercially available microarray platform—
ImmunoCAP ISAC CRD112—in nut allergy [12-14], and 
low specificity has been identified for certain nut components 
such as Jug r 2 [15]. 
The objective of this study was to evaluate the diagnostic 
performance of ImmunoCAP ISAC CRD112 (ISAC) (Thermo 
Fisher Scientific) in the detection of sIgE against peanut, 
hazelnut, and walnut allergen components in a Mediterranean 
area. We also sought to evaluate whether measurement of 
molecular components not included in ISAC might improve 
the diagnosis of nut allergy in our area. 
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Material and Methods
Patients
We enrolled 39 peanut-allergic, 36 hazelnut-allergic, and 
44 walnut-allergic nonpediatric patients (aged ≥14 years) with 
clear IgE-mediated allergic symptoms, a positive skin prick 
test (SPT), and positive sIgE determination (≥0.35 kUA/L 
ImmunoCAP, Thermo Fisher Scientific) to the tree nut(s) 
triggering their allergic reaction. A detailed clinical history 
and a complete questionnaire were obtained from each patient 
regarding demographic characteristics, atopic history, and 
food habits. Symptoms were categorized into oral allergy 
syndrome, systemic symptoms, and anaphylaxis. When 
patients experienced more than 2 types of reactions with the 
same nut, the reaction associated with the severest symptoms 
was recorded as the most serious reaction. Eighty-one controls 
(37 with rhinitis and/or bronchial asthma and sensitized to 
dust mites but not to plant foods or pollen and 44 nonatopic 
controls) were also enrolled. Enrolment was performed in 14 
hospitals across Spain. The study was approved by the ethics 
committee of Clinica Universidad de Navarra (045/2011) and 
this approval was supported by the ethics committees at the 
rest of participating hospitals. 
Skin Prick Tests
SPTs were performed in all participants with commercial 
extracts of peanut, hazelnut, walnut, and peach (30 mg/mL of 
Pru p 3) (ALK Abelló). Sodium chloride (0.9%) and histamine 
hydrochloride (10 mg/mL, ALK-Abelló) served as negative 
and positive controls, respectively. Wheals of 3 mm in diameter 
were considered positive, as recommended by the European 
Academy of Allergy Clinical Immunology guidelines [16].
Multiplex Specific IgE
Specific IgE against rAra h 1, rAra h 2, rAra h 3, rAra h 8, 
rAra h 9, rCor a 1.0410 (from now on referred as Cor a 1), 
rCor a 8, nCor a 9, rJug r 1, nJug r 2, nJug r 3, and rPru p 3, among 
other components, was measured using ISAC in accordance 
with the manufacturer’s instructions. Specific IgE values were 
expressed in ISAC standard units (ISU), with values of 0.3 
ISU or greater considered positive. As the technique is semi-
quantitative, ISU values were grouped into established ranges 
(<0.3 ISU, not detectable; ≥0.3 to <1 ISU, low; ≥1 to <15, 
moderate; and ≥15, very high) following the manufacturer´s 
instructions. 
In nut-allergic patients with a negative result to the 
corresponding nut components in ISAC, sensitization to 
panallergens and other allergen families (LTPs, profilins, PR-
10 proteins, 2s albumin, 11s globulin, and 7s globulin) was 
also analyzed in ISAC.
Single Specific IgE Against Nut Components 
In allergic patients with negative results to nut components 
in ISAC, sIgE against rAra h 1, rAra h 2, rAra h 3, rAra h 8, 
rAra h 9, rCor a 1, rCor a 8, nCor a 9, rCor a 14, Jug r 1, and 
rJug r 3 was measured by fluorescence enzyme immunoassay 
(ImmunoCAP, Thermo Fisher Scientific) following the 
manufacturer’s instructions. Moreover, in peanut-, hazelnut-, 
and walnut-allergic patients with a positive SPT to Pru p 3 
enriched peach extract, sIgE against Ara h 9 (peanut), Cor a 8 
(hazelnut), and Jug r 3 (walnut) was measured. Specific IgE 
against Ara h 9, Cor a 8, and Jug r 3 was also determined by 
ImmunoCAP in 30 randomly selected controls (15 atopic 
and 15 nonatopic). Specific IgE values were quantified in 
kUA/L, and values of 0.35 kUA/L and greater were considered 
positive. 
Specific IgE against nAra h 6 (ETSIA, Universidad 
Politécnica de Madrid)—an allergenic component not 
available in ImmunoCAP—was determined by direct ELISA 
as previously reported [17] in peanut-allergic patients with 
negative sIgE to peanut components in ISAC. The test was 
performed using patient sera at the corresponding dilution 
and rabbit anti-IgE antibody (dilution 1:5000; Biosource). 
Proteins were coated at 5 mg/mL in PBS blocking solution 
(0.1%) (commercial digested casein SIGMA) without a solid 
Table. Clinical and Demographic Characteristics of Patients and Controls 
  Peanut-Allergic  Hazelnut-Allergic Walnut-Allergic Nonatopic Atopic 
  Patients Patients Patients Controls Controls
Individuals, No. 39 36 44 44 37
Age, mean (SD), y 29.7 (9.1) 29.6 (8.7) 31.1 (9.5) 47.3 (15.2) 39.6 (14.2)
Male sex, % 28.2 27.7 36.4 25 37.8
Symptoms caused by  
triggering nut, No. (%) 
 Oral allergy syndrome 13 (33.3) 13 (36.1) 17 (38.6) 0 0 
 Systemic symptoms 16 (41) 13 (36.1) 16 (36.4) 
 Anaphylaxis 10 (25.6) 10 (27.7) 11 (25)
sIgE against nut, median  
(25-75 percentile), kUA/L 1.31 (0.75-5.9) 1.96 (1.03-7.18) 1.73 (1-4.81)  ND ND
Positive Pru p 3 enriched peach  
extract SPT, No. (%) 33 (84.6) 32 (88.9) 38 (86.4) 0 0
Abbreviations: ND, not determined; sIgE, specific IgE; SPT, skin prick test.
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phase. Bovine serum albumin as a solid phase or a serum pool 
from healthy individuals was used as a negative control in 
the different studies and optical density (OD) values greater 
than mean [OD] + 3 x SD with respect to the negative control 
were considered positive. Serum dilution was determined by 
tritration curves.
Statistical Analysis
Quantitative variables were described as means (SD) or 
as medians and interquartile ranges (25-75 percentile) when 
data distribution was not normal. Normality was assessed by 
the Shapiro-Wilk test. Qualitative variables were described 
as frequencies (percentages), and proportions were compared 
using the c2 test. All statistical analyses were performed 
using Stata/IC 12.0. Differences were considered statistically 
significant when the P value was less than .05.
Results
Nut-Allergic Patients 
We enrolled 66 patients with IgE-mediated allergic 
symptoms to peanut (n=39), hazelnut (n=36), or walnut (n=44) 
with a positive SPT and sIgE to the corresponding tree nut(s). 
Eighteen patients were allergic to the 3 nuts, and 46 (69.7%) 
were also allergic to peach. The demographic and clinical data 
for the patients and the 37 atopic and 44 nonatopic controls 
are summarized in the Table.
Protein Microarray Sensitization Profile of  
Nut-Allergic Patients
The ISAC microarray results showed that 66.6% of 
peanut-allergic patients, 80.5% of hazelnut-allergic patients, 
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Figure 1. Sensitization profile of nut-allergic patients according to ImmunoCAP ISAC CRD112. Upper panel, summary of ISAC data regarding 
sensitization to nut allergens. Lower panel, summary of ISAC data regarding sensitization to panallergens and allergen families different from 
nuts. The number of patients sensitized to Pru p 3 is shown in dark gray. LTP indicates lipid transfer protein.
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and 70.4% of walnut-allergic patients were sensitized to the 
corresponding LTP (Ara h 9, Cor a 8, and Jug r 3, respectively) 
and that a small proportion of patients were also sensitized to 
other allergens. One third of peanut-allergic patients (n=13), 
13.9% of hazelnut-allergic patients (n=5), and 13.6% of 
walnut-allergic patients (n=6) did not show sIgE against 
any of nut components in ISAC. Figure 1 summarizes the 
sensitization profiles of nut-allergic patients according to the 
protein microarray results. None of the controls were sensitized 
to peanut components; 1 was sensitized to Cor a 8, 1 to Jug r 2, 
and 2 to Jug r 3. 
Other Sensitizations in Nut-Allergic Patients With 
Negative ISAC Results 
Panallergen sensitization (profilin, PR-10 proteins, 2s 
albumin, 11s globulin, and 7s globulin) was assessed in nut-
allergic patients with negative results to the nut components 
in ISAC. 
Sensitization to LTPs was common among nut-allergic 
patients without detectable sensitization to the triggering 
nut in ISAC. This sensitization was detected in 9 of the 13 
patients with peanut allergy, in 5 of the 5 patients with hazelnut 
allergy, and in 6 of the 6 patients with walnut allergy. Most 
of the patients were sensitized to Pru p 3, and only a few were 
sensitized to PR-10 proteins (1/13 peanut-allergic and 1/6 
walnut-allergic patients), profilins (2/13 peanut-allergic and 
1/6 walnut-allergic patients), or storage proteins (1/13 peanut-
allergic patients to 2s albumin, 1/13 peanut-allergic patients to 
11s globulins, and 1/13 peanut-allergic patients to 7s globulin). 
Only 2 peanut-allergic patients showed no sensitization to 
peanut components or panallergens/storage proteins by ISAC. 
These results are summarized in Figure 1.
Sensitization as Assessed by Alternative Techniques 
in ISAC-Negative Nut-Allergic Patients
sIgE against Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 9 
using ImmunoCAP and Ara h 6 using ELISA was measured 
in the 13 peanut-allergic patients in whom peanut sensitization 
was not detected by ISAC. ImmunoCAP showed sIgE against 
Ara h 9 in 8 of these patients. Of these 8 patients, 5 were also 
Figure 2. Sensitization profile of nut-allergic patients according to ImmunoCAP. Upper panel, summary of ISAC data regarding sensitization to 
nut allergens. Lower panel, summary of ImmunoCAP data regarding sensitization to nut components in nut-allergic patients with negative results 
to nut components in ISAC. sIgE indicates specific IgE.
Ara h 9 +
Ara h 6 + 
Ara h 1 + 
Ara h 2 +
Ara h 3
2.6%
Peanut-allergic patients (n=39) Hazelnut-allergic patients (n=36) Walnut-allergic patients (n=44)
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in Figure 3. sIgE against Ara h 9, Cor a 8, and Jug r 3 using 
ImmunoCAP and the ISAC microarray was measured in all 
patients and controls and then compared.
Serum sIgE against Ara h 9 was detected in more peanut-
allergic peach-sensitized patients by ImmunoCAP (94.4%, 
34/36) than by ISAC (72.2%, 26/36) (2-tailed P=.011). 
However, sIgE to Cor a 8 and to Jug r 3 was detected to a similar 
degree by both techniques in hazelnut-allergic peach-sensitized 
patients (ISAC 85.3% [29/34] vs ImmunoCAP 93.9% [31/33], 
2-tailed P=.247) and walnut-allergic peach-sensitized patients 
(ISAC 85.4% [35/41] vs ImmunoCAP 87.8% [36/41], P=.746]) 
Few controls showed sIgE against Ara h 9 (0/30 by ISAC and 
by ImmunoCAP), Cor a 8 (1/30 by ISAC and by ImmunoCAP), 
or Jug r 3 (2/30 by ISAC and 1/30 by ImmunoCAP). 
Specific IgE against nut LTPs using ImmunoCAP was 
compared with sIgE ranges obtained using ISAC. The data 
are shown in Figure 4.
Discussion 
We confirmed in a well-defined group of patients 
allergic to peanut, hazelnut, and walnut that LTP is the main 
allergen in nut allergy, as has been previously reported in the 
Mediterranean area [6-8,10]. It is important to highlight that 
this study did not include children. This exclusion criterion 
may explain why only a few of the individuals analyzed were 
sensitized to common major allergens (storage proteins), 
since sensitization profiles have been reported to differ 
according to age [18-20]. The differential profile we observed 
sensitized to Ara h 6 according to ELISA. Four of the 13 
patients were only sensitized to Ara h 6 according to alternative 
techniques. No sensitization was detected to Ara h 1, Ara h 2, 
Ara h 3, or Ara h 8 by ImmunoCAP in any of the ISAC-negative 
peanut-allergic patients. 
sIgE against Cor a 1, Cor a 8, Cor a 9, and Cor a 14 was 
determined by ImmunoCAP in the 5 hazelnut-allergic patients 
in whom hazelnut sensitization was not detected by ISAC. 
Three patients were found to be sensitized to Cor a 8. No 
sensitization was detected for Cor a 1, Cor a 9, or Cor a 14 by 
CAP in any of the 5 ISAC-negative hazelnut-allergic patients. 
sIgE against Jug  r 1 and Jug r 3 was measured by 
ImmunoCAP in the 6 walnut-allergic patients in whom no 
walnut sensitization was detected by ISAC. ImmunoCAP 
showed 5 of the patients to be sensitized to Jug r 3 and none 
of the patients to be sensitized to Jug r 1. These data are 
summarized in Figure 2. 
Diagnostic Performance of the ISAC Microarray for 
Nut LTPs 
In order to assess the diagnostic performance of peanut, 
hazelnut, and walnut LTPs in ISAC, LTP-sensitized nut-
allergic patients were selected from our sample together 
with 30 controls (15 nonatopic controls and 15 atopic dust 
mite–allergic patients without plant allergen sensitization) 
randomly selected from the control group. LTP sensitization 
was defined as a positive SPT to Pru p 3 enriched peach. Serum 
sIgE against peanut, hazelnut, and walnut LTPs was measured 
by ImmunoCAP. The flow chart of this subgroup is presented 
Figure 3. Specific IgE against nut LTPs according to CAP and ISAC in peach-sensitized peanut-, hazelnut-, walnut-allergic patients. Patients with 
serum available for ImmunoCAP determination are shown in brackets. SPT indicates skin prick test; sIge, specific IgE.
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with regard to other series may also have been influenced by 
geographic location [6,20].
We also observed that not all nut-allergic patients were 
diagnosed by the ISAC protein microarray, since 33.3% of 
peanut-allergic patients (13/39), 13.9% of hazelnut-allergic 
patients (5/36), and 13.6% walnut-allergic patients (6/44) did 
not show any sIgE against proteins from the nut responsible 
for their symptoms. Interestingly, Ara h 9 sensitization was 
detected by the consolidated ImmunoCAP in 8 of the 13 
peanut-allergic patients with ISAC-negative results, suggesting 
that ISAC performs poorly in the detection of peanut LTP 
sensitization. 
To assess the diagnostic performance of ISAC for the 
detection of sIgE to peanut, hazelnut, and walnut LTPs, we 
selected a subgroup of LTP-sensitized nut-allergic patients 
and controls. Based on the sIgE results from ImmunoCAP 
and ISAC against Ara h 9, Cor a 8, and Jug r 3 in this sample 
we can conclude that the sensitivity of the peanut LTP Ara h 9 
needs to be improved in the ISAC platform, since ImmunoCAP 
outperformed ISAC in diagnosing cases of sensitization to 
Ara h 9 in peanut-allergic patients. Furthermore, this low 
diagnostic capacity in ISAC cannot be explained by low levels 
of sIgE, since according to ISAC, considerable sIgE values 
as determined by ImmunoCAP (including values >20 kUA/L 
for Ara h 9) were recorded as undetectable (Figure 4A). 
Moreover, these discrepancies in sIgE values between ISAC 
and ImmunoCAP were also observed for Cor a 8 (Figure 4B) 
and Jug r 3 (Figure 4C). In the case of Jug r 3, the recombinant 
form is used in ImmunoCAP, while the natural form is used in 
ISAC. However, in the case of Ara h 9 and Cor a 8, according 
to the manufacturer’s information, the recombinant forms of 
both these proteins are used in both tests. These data suggest 
that Ara h 9 and Cor a 8 underwent a different folding process 
in the ISAC slide than in the ImmunoCAP polymer and this 
may have affected IgE binding.
Because Pru  p 3 shows high cross-reactivity with 
Ara h 9 [21] and Jug r 3 [9], in addition to significant cross-
reactivity with Cor a 8 [22], in the Mediterranean area, the 
inclusion of this LTP in nut CRD diagnosis by ISAC helps 
to detect otherwise ISAC-negative patients. In fact, in ISAC, 
positive sIgE against specific nut components in addition 
to Pru p 3 diagnosed 87.2% (34/39) of all peanut-allergic 
Figure 4. Specific IgE (sIgE) against nut lipid transfer proteins by CAP regarding ISAC sIgE ranges in peach-LTP-sensitized peanut-, hazelnut-, 
walnut-allergic patients.
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patients, 97.2% (35/36) of all hazelnut-allergic patients, and 
100% (44/44) of all walnut-allergic patients compared with 
positive sIgE against specific nut components only (peanut, 
26/36 [72.2%], hazelnut, 31/36 [86.1%], walnut, 38/44 
[86.4%]). Although it has been suggested that a limited set 
of well-validated sensitization markers rather than a panel 
of components for CRD can facilitate allergy diagnosis [23], 
Pru p 3 sensitization does not determine clinical reactivity to 
nuts as has been previously reported [10]. In conclusion, after 
confirming that LTP is the main allergen in peanut-, hazelnut-, 
and walnut-allergic patients in our area, we demonstrated that 
the sensitivity of the ISAC protein microarray can vary between 
certain allergens. In particular, the sensitivity of certain LTPs, 
such as the peanut LTP Ara h 9, needs to be improved in ISAC.
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